Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Navaie, Will"'
Autor:
Sydes, Matthew R, Barbachano, Yolanda, Bowman, Louise, Denwood, Tom, Farmer, Andrew, Garfield-Birkbeck, Steph, Gibson, Martin, Gulliford, Martin C, Harrison, David A, Hewitt, Catherine, Logue, Jennifer, Navaie, Will, Norrie, John, O'Kane, Martin, Quint, Jennifer K, Rycroft-Malone, Jo, Sheffield, Jonathan, Smeeth, Liam, Sullivan, Frank, Tizzard, Juliet, Walker, Paula, Wilding, John, Williamson, Paula R, Landray, Martin, Morris, Andrew, Walker, Rhoswyn R, Williams, Hywel C, Valentine, Janet, Data Enabled Trials Group Workshop Group Members
RATIONALE: Clinical trials are the gold standard for testing interventions. COVID-19 has further raised their public profile and emphasised the need to deliver better, faster, more efficient trials for patient benefit. Considerable overlap exists bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b73eff5688b03d7563ab17a0364ce048
https://www.repository.cam.ac.uk/handle/1810/322125
https://www.repository.cam.ac.uk/handle/1810/322125
Autor:
Blagden, Sarah P., Billingham, Lucinda, Brown, Louise C., Buckland, Sean W., Cooper, Alison M., Ellis, Stephanie, Fisher, Wendy, Hughes, Helen, Keatley, Debbie A., Maignen, Francois M., Morozov, Alex, Navaie, Will, Pearson, Sarah, Shaaban, Abeer, Wydenbach, Kirsty, Kearns, Pamela R., Abouzeid, Christiane, Ahmed, Rubina, Bailey, Sue, Blewett, Catherine, Campbell, Helen, Cerone, Maria Antonietta, Clack, Glen, Cook, Natalie, Ghiorghiu, Serban, Halford, Sarah, Johnston, Andrew, Kaplan, Rick, Lawson, Anna, Lowe, Emma, Mathews, Jacqueline, Mirabile, Ilaria, Osipenko, Leeza, Patel, Dipak, Potter, Claire, Regan, Aoife, Ricamara, Marivic, Ringrose, Carly, Rodger, Joanne, Sandhu, Gurcharan K., Schiavone, Francesca, Silvester, Julie, Sydes, Matthew R., Weller, Charles, Yiangou, Angeliki
Publikováno v:
Blagden, S P, Billingham, L, Brown, L C, Buckland, S W, Cooper, A M, Ellis, S, Fisher, W, Hughes, H, Keatley, D A, Maignen, F M, Morozov, A, Navaie, W, Pearson, S, Shaaban, A, Wydenbach, K, Kearns, P R, Abouzeid, C, Ahmed, R, Bailey, S, Blewett, C, Campbell, H, Cerone, M A, Clack, G, Cook, N, Ghiorghiu, S, Halford, S, Johnston, A, Kaplan, R, Lawson, A, Lowe, E, Mathews, J, Mirabile, I, Osipenko, L, Patel, D, Potter, C, Regan, A, Ricamara, M, Ringrose, C, Rodger, J, Sandhu, G K, Schiavone, F, Silvester, J, Sydes, M R, Weller, C & Yiangou, A 2020, ' Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement ', British Journal of Cancer, vol. 122, no. 4, pp. 473-482 . https://doi.org/10.1038/s41416-019-0653-9
British Journal of Cancer
British Journal of Cancer
The traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::846940b5843ad1cda6b83f6951fb7836
https://doi.org/10.1038/s41416-019-0653-9
https://doi.org/10.1038/s41416-019-0653-9
Autor:
Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK m.sydes@ucl.ac.uk., Barbachano Y; Medicines and Healthcare products Regulatory Agency (MHRA), London, UK., Bowman L; MRC Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Denwood T; NHS Digital, Leeds, UK., Farmer A; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Garfield-Birkbeck S; Trials and Studies Coordinating Centre, National Institute for Health Research Evaluation, Southampton, UK., Gibson M; North West E‑Health (NWEH) Ltd, Manchester, UK., Gulliford MC; King's College London, London, UK.; NIHR Biomedical Research Centre at Guy's and St Thomas' Hospitals London, London, UK., Harrison DA; Intensive Care National Audit & Research Centre (ICNARC), London, UK., Hewitt C; York Trials Unit, Department of Health Sciences, The University of York, York, UK., Logue J; Lancaster University, Lancaster, UK., Navaie W; Health Research Authority, London, UK., Norrie J; Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK., O'Kane M; Medicines and Healthcare products Regulatory Agency (MHRA), London, UK., Quint JK; Department of Respiratory Epidemiology, Occupational Medicine and Public Health, Imperial College London, London, UK., Rycroft-Malone J; Lancaster University, Lancaster, UK.; NIHR Health Services & Delivery Programme, Southampton, UK., Sheffield J; NIHR Clinical Research Network, University of Leeds, Leeds, UK., Smeeth L; Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK., Sullivan F; Division of Population & Behavioural Science, University of St. Andrews, St Andrews, UK.; Department of Family & Community Medicine, University of Toronto, Toronto, Ontario, Canada., Tizzard J; Health Research Authority, London, UK., Walker P; Medicines and Healthcare products Regulatory Agency (MHRA), London, UK., Wilding J; Department of Cardiovasular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK., Williamson PR; Department of Health Data Science, University of Liverpool, Liverpool, UK., Landray M; Nuffield Department of Population Health, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Health Data Research UK, University of Oxford, Oxford, UK., Morris A; Health Data Research UK, London, UK., Walker RR; Health Data Research UK, London, UK., Williams HC; University of Nottingham, Nottingham, UK.; Director of the NIHR Health Technology Assessment Programme (2015-2020), Southampton, UK., Valentine J; Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.
Publikováno v:
BMJ open [BMJ Open] 2021 Jun 16; Vol. 11 (6), pp. e043906. Date of Electronic Publication: 2021 Jun 16.
Autor:
Blagden SP; Department of Oncology, University of Oxford, Oxford, UK. sarah.blagden@oncology.ox.ac.uk., Billingham L; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Studies, University of Birmingham, Birmingham, UK., Brown LC; Medical Research Council (MRC) Clinical Trials Unit, University College London, London, UK., Buckland SW; Pfizer, Surrey, UK., Cooper AM; The Association of the British Pharmaceutical Industry (ABPI), London, UK., Ellis S; Health Research Authority, London, UK., Fisher W; Wendy Fisher Consulting (WFC) Ltd, London, UK., Hughes H; Cardiff and Vale University Health Board, Cardiff, UK., Keatley DA; Independent Cancer Patients' Voice, National Cancer Research Institute (NCRI), London, UK., Maignen FM; National Institute for Health and Care Excellence (NICE), London, UK., Morozov A; Pfizer, New York, USA., Navaie W; Health Research Authority, London, UK., Pearson S; Oncology Clinical Trials Office, University of Oxford, Oxford, UK., Shaaban A; Queen Elizabeth Hospital Birmingham and the University of Birmingham, Birmingham, UK., Wydenbach K; Medicines and Healthcare products Regulatory Agency (MHRA), London, UK., Kearns PR; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Studies, University of Birmingham, Birmingham, UK.; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Studies, University of Birmingham, Birmingham, UK.
Publikováno v:
British journal of cancer [Br J Cancer] 2020 Feb; Vol. 122 (4), pp. 473-482. Date of Electronic Publication: 2020 Jan 06.